# A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

> **NCT06752746** · PHASE1 · RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 108 (estimated)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** 9MW3011

## Key facts

- **NCT ID:** NCT06752746
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-21
- **Primary completion:** 2025-08-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06752746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06752746, "A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06752746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*